- Home
- TORO vs TPST Comparison
TORO vs TPST Comparison
Compare TORO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- TPST
- Stock Information
- Founded
- TORO 2022
- TPST 2011
- Country
- TORO Cyprus
- TPST United States
- Employees
- TORO N/A
- TPST N/A
- Industry
- TORO Marine Transportation
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- TPST Health Care
- Exchange
- TORO Nasdaq
- TPST Nasdaq
- Market Cap
- TORO 36.7M
- TPST 33.0M
- IPO Year
- TORO N/A
- TPST N/A
- Fundamental
- Price
- TORO $2.88
- TPST $6.85
- Analyst Decision
- TORO
- TPST Hold
- Analyst Count
- TORO 0
- TPST 3
- Target Price
- TORO N/A
- TPST $30.00
- AVG Volume (30 Days)
- TORO 428.0K
- TPST 87.0K
- Earning Date
- TORO 08-11-2025
- TPST 08-07-2025
- Dividend Yield
- TORO N/A
- TPST N/A
- EPS Growth
- TORO N/A
- TPST N/A
- EPS
- TORO 1.09
- TPST N/A
- Revenue
- TORO $22,394,283.00
- TPST N/A
- Revenue This Year
- TORO N/A
- TPST N/A
- Revenue Next Year
- TORO N/A
- TPST N/A
- P/E Ratio
- TORO $2.60
- TPST N/A
- Revenue Growth
- TORO 0.40
- TPST N/A
- 52 Week Low
- TORO $1.70
- TPST $5.35
- 52 Week High
- TORO $4.05
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- TORO 69.23
- TPST 47.98
- Support Level
- TORO $2.12
- TPST $6.88
- Resistance Level
- TORO $3.19
- TPST $7.64
- Average True Range (ATR)
- TORO 0.19
- TPST 0.26
- MACD
- TORO 0.08
- TPST -0.01
- Stochastic Oscillator
- TORO 62.84
- TPST 29.25
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.